These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27373200)

  • 1. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.
    Ami D; Lavatelli F; Rognoni P; Palladini G; Raimondi S; Giorgetti S; Monti L; Doglia SM; Natalello A; Merlini G
    Sci Rep; 2016 Jul; 6():29096. PubMed ID: 27373200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
    Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
    Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
    Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
    PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
    Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
    FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
    Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
    J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.
    Imperlini E; Gnecchi M; Rognoni P; Sabidò E; Ciuffreda MC; Palladini G; Espadas G; Mancuso FM; Bozzola M; Malpasso G; Valentini V; Palladini G; Orrù S; Ferraro G; Milani P; Perlini S; Salvatore F; Merlini G; Lavatelli F
    Sci Rep; 2017 Nov; 7(1):15661. PubMed ID: 29142197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
    Ward JE; Ren R; Toraldo G; Soohoo P; Guan J; O'Hara C; Jasuja R; Trinkaus-Randall V; Liao R; Connors LH; Seldin DC
    Blood; 2011 Dec; 118(25):6610-7. PubMed ID: 21998211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis.
    Morgan GJ
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34208058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin light chain amyloid aggregation.
    Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
    Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
    Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
    J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
    Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
    J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
    Pradhan T; Annamalai K; Sarkar R; Huhn S; Hegenbart U; Schönland S; Fändrich M; Reif B
    J Biol Chem; 2020 Dec; 295(52):18474-18484. PubMed ID: 33093170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
    Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
    Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
    Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
    Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
    Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
    Elife; 2020 Mar; 9():. PubMed ID: 32151314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CDR1 and Other Regions of Immunoglobulin Light Chains are Hot Spots for Amyloid Aggregation.
    Ruiz-Zamora RA; Guillaumé S; Al-Hilaly YK; Al-Garawi Z; Rodríguez-Alvarez FJ; Zavala-Padilla G; Pérez-Carreón JI; Rodríguez-Ambriz SL; Herrera GA; Becerril-Luján B; Ochoa-Leyva A; Melendez-Zajgla J; Serpell L; Del Pozo-Yauner L
    Sci Rep; 2019 Feb; 9(1):3123. PubMed ID: 30816248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Process of Amyloid Formation due to Monoclonal Immunoglobulins.
    Morgan GJ; Wall JS
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1041-1054. PubMed ID: 33099422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
    Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
    Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
    Zhang C; Huang X; Li J
    Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.
    Ramirez-Alvarado M; Barnidge DR; Murray DL; Dispenzieri A; Marin-Argany M; Dick CJ; Cooper SA; Nasr SH; Ward CJ; Dasari S; Jiménez-Zepeda VH; Leung N
    Am J Hematol; 2017 Jun; 92(6):536-541. PubMed ID: 28295502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.